Jeffrey J Tomaszewski1, Elizabeth Handorf2, Anthony T Corcoran1, Yu-Ning Wong3, Reza Mehrazin1, Justin E Bekelman4, Daniel Canter5, Alexander Kutikov1, David Y T Chen1, Robert G Uzzo1, Marc C Smaldone6. 1. Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, Pennsylvania. 2. Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center-Temple University Health System, Philadelphia, Pennsylvania. 3. Division of Medical Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, Pennsylvania. 4. Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. 5. Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, Pennsylvania; Department of Urology, Einstein Healthcare Network/Urologic Institute of Southeastern Pennsylvania, Philadelphia, Pennsylvania. 6. Division of Urologic Oncology, Fox Chase Cancer Center-Temple University Health System, Philadelphia, Pennsylvania. Electronic address: marc.smaldone@fccc.edu.
Abstract
PURPOSE: Hypothesizing that changing hospitals between diagnosis and definitive therapy (care transition) may delay timely treatment, we identified the association between care transitions and a treatment delay of 3 months or greater in patients with muscle invasive bladder cancer. MATERIALS AND METHODS: Using the National Cancer Database we identified all patients with stage II or greater urothelial carcinoma treated from 2003 to 2010. Care transition was defined as a change in hospital from diagnosis to definitive treatment course, that is diagnosis to radical cystectomy or the start of neoadjuvant chemotherapy. Logistic regression models were used to test the association between care transition and treatment delay. RESULTS: Of 22,251 patients 14.2% experienced a treatment delay of 3 months or greater and this proportion increased with time (13.5% in 2003 to 2006 vs 14.8% in 2007 to 2010, p = 0.01). Of patients who underwent a care transition 19.4% experienced a delay to definitive treatment compared to 10.7% diagnosed and treated at the same hospital (p <0.001). The proportion of patients with a care transition increased during the study period (37.4% in 2003 to 2006 vs 42.3% in 2007 to 2010, p <0.001). After adjustment patients were more likely to experience a treatment delay when undergoing a care transition (OR 2.0, 95% CI 1.8-2.2). CONCLUSIONS: Patients with muscle invasive bladder cancer who underwent a care transition were more likely to experience a treatment delay of 3 months or greater. Strategies to expedite care transitions at the time of hospital referral may improve quality of care.
PURPOSE: Hypothesizing that changing hospitals between diagnosis and definitive therapy (care transition) may delay timely treatment, we identified the association between care transitions and a treatment delay of 3 months or greater in patients with muscle invasive bladder cancer. MATERIALS AND METHODS: Using the National Cancer Database we identified all patients with stage II or greater urothelial carcinoma treated from 2003 to 2010. Care transition was defined as a change in hospital from diagnosis to definitive treatment course, that is diagnosis to radical cystectomy or the start of neoadjuvant chemotherapy. Logistic regression models were used to test the association between care transition and treatment delay. RESULTS: Of 22,251 patients 14.2% experienced a treatment delay of 3 months or greater and this proportion increased with time (13.5% in 2003 to 2006 vs 14.8% in 2007 to 2010, p = 0.01). Of patients who underwent a care transition 19.4% experienced a delay to definitive treatment compared to 10.7% diagnosed and treated at the same hospital (p <0.001). The proportion of patients with a care transition increased during the study period (37.4% in 2003 to 2006 vs 42.3% in 2007 to 2010, p <0.001). After adjustment patients were more likely to experience a treatment delay when undergoing a care transition (OR 2.0, 95% CI 1.8-2.2). CONCLUSIONS:Patients with muscle invasive bladder cancer who underwent a care transition were more likely to experience a treatment delay of 3 months or greater. Strategies to expedite care transitions at the time of hospital referral may improve quality of care.
Authors: John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: Anthony T Corcoran; Elizabeth Handorf; Daniel Canter; Jeffrey J Tomaszewski; Justin E Bekelman; Simon P Kim; Robert G Uzzo; Alexander Kutikov; Marc C Smaldone Journal: BJU Int Date: 2014-07-14 Impact factor: 5.588
Authors: Brent K Hollenbeck; Rodney L Dunn; David C Miller; Stephanie Daignault; David A Taub; John T Wei Journal: J Clin Oncol Date: 2007-01-01 Impact factor: 44.544
Authors: Erin J Aiello Bowles; Leah Tuzzio; Cheryl J Wiese; Beth Kirlin; Sarah M Greene; Steven B Clauser; Edward H Wagner Journal: Cancer Date: 2008-02-15 Impact factor: 6.860
Authors: Eliza W Beal; Rittal Mehta; Katiuscha Merath; Diamantis I Tsilimigras; J Madison Hyer; Anghela Paredes; Mary E Dillhoff; Jordan Cloyd; Aslam Ejaz; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2019-05-08 Impact factor: 3.452
Authors: Tracy L Rose; Allison M Deal; Ethan Basch; Paul A Godley; W Kimryn Rathmell; William Y Kim; Young E Whang; Mary W Dunn; Andrew Wang; Ronald C Chen; Matthew E Nielsen; Raj S Pruthi; Eric M Wallen; Michael E Woods; Angela B Smith; Matthew I Milowsky Journal: Urol Oncol Date: 2015-06-27 Impact factor: 3.498
Authors: Katia Noyes; John R T Monson; Irfan Rizvi; Ann Savastano; James S A Green; Nick Sevdalis Journal: J Oncol Pract Date: 2016-09-30 Impact factor: 3.840